CLASS G AUTOANTIBODIES TO OXIDATIVELY MODIFIED LOW DENSITY LIPOPROTEIN IN TYPE 2 DIABETES MELLITUS PATIENTS WHO HAVE HAD NON-Q-MYOCARDIAL INFARCTION
DOI:
https://doi.org/10.21856/j-PEP.2015.3.01Keywords:
type 2 diabetes mellitus, myocardial infarction, autoantibodies to oxidized lowdensity lipoproteinAbstract
The article presents the results of a study of class G autoantibodies to oxidatively modified low-density lipoprotein (ox-LDL) in patients with type 2 diabetes mellitus which have had non-Qmyocardial infarction and their connection with disturbances of carbohydrate and lipid metabolism, the levels of cytokines. It was identified the decrease level of IgG to ox-LDL in the serum of these patients compared with the control group and patients without diabetes. The study found that with increasing degree of insulin resistance, the concentration of class G autoantibodies to ox-LDL in diabetic postinfarction patients was reduced. It was also revealed their direct connection with the level of anti-inflammatory IL-10. The data obtained may be evidence of the negative impact of carbohydrate metabolism disorders on the level of IgG autoantibodies to ox-LDL and the data may refer to their protective role in type 2 diabetes mellitus with concomitant atherosclerosis.
References
Fefelova EV, Khyshyktuev BS, Maksymenia MV, et al. Dalnevostochnyi Med Zhurn 2013; 1:6-8.
Moohebati M, Kabirirad V, Ghayour-Mobarhan M, et al. Int J Vasc Med 2014; 845960.
Zhdanova OIu. Autoantytela k modyfytsyrovannym lypoproteynam cheloveka y ykh rol v ateroheneze, Sankt-Peterburg, 2005: 117 p.
Hunt KJ, Baker N, Cleary P, et al. Atherosclerosis 2013; 231(2):315–322.
Crisby M, Henareh L, Agewall S. Angiology 2013; November 27.
Lopes-Virella MF, Baker NL, Hunt KJ, et al. Atherosclerosis 2011; 214(2):462–467.
Santos AO, Fonsea FA, Fischer SM, et al. Clin Chim Acta 2009; 406(1–2):113–118.
Garrido-Sanchez L, Garcia-Pinilla JM, JimenezNavarro M, et al. Clin Lab 2011; 57(11–12):901–907.
Shoenfeld Y, Wu R, Dearing LD, et al. Circulation 2004; 110(17):2552–2558.
Hruzdeva OV, Barbarash OL, Palycheva EY, et al. Klyn Lab Dyahnost 2011; 7:14–17.
Ryden L, Grant PJ, Anker SD, et al. Eur Heart J 2013; 34:3035-3087.
Friedewald WT, Levy RI, Fredricson DS. Clin. Chem 1972; 18:499-502.
Babakr AT, Elsheikh OM, Almarzouki AA, et al. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2014; 7:513-520.
Sampi M, Veneskoski M, Ukkola O, et al. J Clin Endocrinol Metab 2010; 95(5):2467-2475.
Erkkila AT, Narvanen O, Lehto S, et al. Arterioscler Thromb Vasc Biol 2000; 20(1):204-209.
Inoue T, Uchida T, Kamishirado H, et al. J Amer Coll Cardiol 2001; 37(3):775-779.
Laczik R, Szodoray P, Veres K, et al. Lupus 2011; 20(7):730-735.
Rahsepar AA, Mirzaee A, Moodi F, et al. Cardiology 2012; 122(4):203-209
Fonseca HA, Fonceca FA, Monteiro AM, et al. Cell Biochem Biophys 2013; 67(3):1451-1460.
Zhu L, He Z, Wu F, et al. Cardiovasc Diabetol 2014; 13:151.
ISSN 
ISSN 
